Cancidas is a drug owned by Merck And Co Inc. It is protected by 10 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 28, 2017. Details of Cancidas's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6136783 (Pediatric) | Antifungal compositions |
Sep, 2017
(7 years ago) |
Expired
|
|
US5952300 (Pediatric) | Antifungal compositions |
Sep, 2017
(7 years ago) |
Expired
|
| US6136783 | Antifungal compositions |
Mar, 2017
(7 years ago) |
Expired
|
| US5952300 | Antifungal compositions |
Mar, 2017
(7 years ago) |
Expired
|
|
US5514650 (Pediatric) | Aza cyclohexapeptide compounds |
Jul, 2015
(9 years ago) |
Expired
|
| US5514650 | Aza cyclohexapeptide compounds |
Jan, 2015
(9 years ago) |
Expired
|
|
US5378804 (Pediatric) | Aza cyclohexapeptide compounds |
Sep, 2013
(11 years ago) |
Expired
|
|
US5792746 (Pediatric) | Aza cyclohexapeptide compounds |
Sep, 2013
(11 years ago) |
Expired
|
| US5378804 | Aza cyclohexapeptide compounds |
Mar, 2013
(11 years ago) |
Expired
|
| US5792746 | Aza cyclohexapeptide compounds |
Mar, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Cancidas is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cancidas's family patents as well as insights into ongoing legal events on those patents.
Cancidas's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cancidas's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 28, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cancidas Generic API suppliers:
Caspofungin Acetate is the generic name for the brand Cancidas. 6 different companies have already filed for the generic of Cancidas, with Areva Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cancidas's generic
How can I launch a generic of Cancidas before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Cancidas's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Cancidas's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Cancidas -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 50 mg/vial and 70 mg/vial | 26 Jun, 2009 | 1 | 28 Mar, 2017 | Extinguished |
Alternative Brands for Cancidas
Cancidas which is used for treating presumed fungal infections in febrile, neutropenic patients., has several other brand drugs using the same active ingredient (Caspofungin Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Fresenius Kabi Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Caspofungin Acetate, Cancidas's active ingredient. Check the complete list of approved generic manufacturers for Cancidas
About Cancidas
Cancidas is a drug owned by Merck And Co Inc. It is used for treating presumed fungal infections in febrile, neutropenic patients. Cancidas uses Caspofungin Acetate as an active ingredient. Cancidas was launched by Merck in 2001.
Approval Date:
Cancidas was approved by FDA for market use on 26 January, 2001.
Active Ingredient:
Cancidas uses Caspofungin Acetate as the active ingredient. Check out other Drugs and Companies using Caspofungin Acetate ingredient
Treatment:
Cancidas is used for treating presumed fungal infections in febrile, neutropenic patients.
Dosage:
Cancidas is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG/VIAL | POWDER | Prescription | INTRAVENOUS |
| 70MG/VIAL | POWDER | Prescription | INTRAVENOUS |